Leap Investments’s Pacira BioSciences PCRX Stock Holding History

Leap Investments’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,400	Closed	-$235K	–	466
2019 Q2	$235K	Buy	+5,400	New	+$229K	0.32%	130

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Leap Investments's PCRX Position: Q3 2019 in Review

Leap Investments sold out of Pacira BioSciences (PCRX) in Q3 2019, closing a stake of 5,400 shares — an estimated $235K sold.

Leap Investments first reported a position in PCRX in Q2 2019 and held it in 1 quarter. The position peaked at $235K in Q2 2019. 211 funds tracked by Wall St. Rank hold PCRX as of Q3 2019.

Leap Investments reported no remaining Pacira BioSciences position as of Q3 2019 after selling out during the quarter.
Leap Investments sold 5,400 Pacira BioSciences shares in Q3 2019, an estimated $235K.
Leap Investments first reported a position in Pacira BioSciences in Q2 2019 and held it in 1 quarter.
Leap Investments's Pacira BioSciences position peaked at $235K in Q2 2019.
211 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.